Advertise on podcast: Revenue Rx

Under Medicare Part A, administering an expensive medication doesn't necessarily mean a hospital receives additional reimbursement. In this episode of Revenue Rx, we break down how Medicare reimburses inpatient hospital stays, why most medications are included in bundled payments, and what that means for pharmacy financial performance. From understanding MS-DRGs to managing high-cost therapies, we'll explore why protecting the margin under Medicare Part A requires a different approach to pharmacy revenue cycle management. Key TakeawaysMedicare Part A generally pays hospitals based on MS-DRGs, not individual medications.Higher costs ≠ higher payments: Expensive drugs don't automatically increase reimbursement.Accurate charges support cost accounting, utilization analysis, and reimbursement.Outlier payments and NTAP may provide additional reimbursement for qualifying cases.Managing drug costs, monitoring utilization, and maintaining accurate charge capture are essential.Chapters00:02 Introduction: Medicare Part A 01:01 Medicare Eligibility & Coverage 02:58 Inpatient Reimbursement: IPPS & MS-DRGs 04:10 How Bundled Payments Impact Pharmacy 05:05 Why Charge Capture Still Matters 06:09 High-Cost Drugs, Outliers & NTAP 07:23 Pharmacy Revenue Cycle Priorities 08:18 Key Takeaways & What's Next 09:12 Disclaimer ReferencesMedicare.gov: Get Started with MedicareCMS: Acute Inpatient Prospective Payment System (IPPS)CMS: Inpatient Prospective Payment System OverviewCMS: Outlier PaymentsCMS: New Medical Services and New Technologies (NTAP)DisclaimerThis podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

How did Medicare and Medicaid evolve into one of the most influential forces shaping healthcare reimbursement? In this episode of Revenue Rx, we explore more than 60 years of healthcare policy, from the creation of Medicare and Medicaid in 1965 to prospective payment systems, Medicare Part D, and modern drug pricing reform. Discover how these milestones shaped pharmacy reimbursement, hospital finances, and the revenue cycle we navigate today. Takeaways How Medicare and Medicaid transformed healthcare financing in 1965.Why the introduction of DRGs in 1983 changed hospital reimbursement and pharmacy cost management.How CHIP expanded healthcare coverage for children.How OPPS introduced APCs, drug packaging, and separate payment methodologies.Why Medicare Part D reshaped outpatient prescription drug coverage.How the Affordable Care Act and CMMI accelerated payment innovation.Why Medicare drug price negotiation represents another turning point in pharmaceutical reimbursement.How understanding CMS history helps pharmacy and revenue cycle teams prepare for future policy changes.Chapters 00:43 1965: The Birth of Medicare and Medicaid 03:04 1977: From HCFA to CMS 03:39 1983: The DRG Revolution 05:29 1997: Expanding Coverage Through CHIP 06:05 2000: The Rise of OPPS 07:18 2003: Medicare Part D Changes Pharmacy 08:33 2010: The Affordable Care Act and CMMI 09:23 2022: Medicare Drug Price Negotiation 10:05 Why CMS History Matters Today 12:30 Disclaimer References CMS: HistoryMedicare: Medicare & YouCMS: Hospital Inpatient Prospective Payment SystemsCMS: Hospital Outpatient PPSMedicaid: Children's Health Insurance ProgramCMS Innovation CenterCMS: Medicare Drug Price Negotiation ProgramDisclaimer This podcast is for informational and educational purposes only. The views shared are my own and do not represent any organization I am affiliated with. This is not legal, financial, or reimbursement advice, and you should consult your internal experts before making decisions.

CMS has finalized the GLOBE Model, introducing international drug pricing benchmarks for select Medicare Part B drugs. But the final rule looks significantly different from the original proposal. In this episode of Revenue RX, Lubna Mazin breaks down what changed, how reduced patient coinsurance affects provider reimbursement, and what pharmacy revenue cycle, finance, and patient financial services teams need to know before implementation begins in 2027. Takeaways GLOBE is a mandatory five-year Medicare Part B model using international pricing benchmarks to calculate manufacturer rebates.The final rule narrows participation to approximately 25% of eligible Original Medicare beneficiaries and reduces projected Medicare savings from $2.3 billion to approximately $80 million.Reduced patient coinsurance does not reduce the provider's Medicare allowed payment. Medicare increases its share to offset the difference.Beneficiary eligibility is based on the patient's address of record, not the hospital's location.No special billing modifier or separate billing system is required, but inaccurate patient estimates could create overcollections and refunds.Organizations should evaluate drug exposure, prepare patient financial services, validate reimbursement and reconciliation workflows, and assign ongoing oversight.Chapters 00:00 Introduction to the GLOBE Model 00:46 What Is the GLOBE Model? 01:00 International Drug Pricing Benchmarks 02:19 Implementation Timeline 02:49 What Changed Between the Proposed and Final Rule? 05:06 Provider Reimbursement and Revenue Cycle Impact 07:40 Five Steps to Prepare for GLOBE References CMS GLOBE Model Final RuleCMS GLOBE Model Frequently Asked Questions (FAQ)Disclaimer This podcast is for informational and educational purposes only. The views shared are my own and do not represent any organization I am affiliated with. This is not legal, financial, or reimbursement advice, and you should consult your internal experts before making decisions.

The 340B Rebate Model Pilot Program begins January 1, 2027, bringing significant changes to how covered entities access 340B savings. In this episode, we break down the 10 participating manufacturers, 22 affected drugs, rebate timelines, claims requirements, and financial implications of moving from upfront discounts to retrospective rebates. Learn how this shift impacts cash flow, reconciliation, and pharmacy operations, along with five practical steps organizations can take to prepare. Takeaways 10 manufacturers and 22 drugs are included in the pilot.Covered entities will pay WAC upfront and receive 340B savings through rebates.Claims must be submitted within 45 days, with manufacturers required to pay or deny complete submissions within 10 days.Cash flow, rebate tracking, and reconciliation will become critical.Pharmacy and finance teams should prepare workflows, systems, and accountability before January 2027.Chapters 01:06 How the 340B Rebate Model Works 02:44 10 Manufacturers and 22 Drugs Included 04:31 Rebate Rules, Timelines, and Claims Requirements 07:35 Cash Flow, Reconciliation, and Financial Impact 08:24 Rebate Denials and HRSA Protections 09:37 5 Steps to Prepare for January 2027 12:15 Disclaimer References HRSA 340B Drug Pricing Program HRSA 340B Rebate Model Pilot Program and Approved Manufacturer Plans Disclaimer This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

The October 2026 CMS HCPCS Quarterly Update brings more than a routine list of new and deleted codes. This quarter includes major changes to billing units, manufacturer-specific HCPCS codes, new oncology and biosimilar codes, revised descriptions, and at least one discrepancy between a CMS coding determination and the published quarterly file. Update: J0014 Cocaine hydrochloride nasal solution (Goprelto), 1 mg was added to https://www.cms.gov/files/zip/october... on 09/23/2026. Takeaways Billing-unit changes are one of the most significant risks in the October 2026 HCPCS update.Oncology drugs including etoposide, fluorouracil, and trabectedin have substantial billing-increment changes that can materially affect reimbursement.A successful HCPCS update is not complete until claims are adjudicating and reimbursing correctly. Chapters 00:00 October 2026 HCPCS Quarterly Update 01:16 505(b)(2) Drug Code Changes 06:22 Oncology Drugs 08:18 New HCPCS Drug Codes 09:28 New Biosimilar HCPCS Codes 09:54 CMS File Discrepancy 11:09 Revised HCPCS Descriptions 11:46 October HCPCS Go-Live Checklist References https://www.cms.gov/medicare/coding-b... https://www.cms.gov/files/document/20... https://www.cms.gov/files/zip/october... Disclaimer This podcast is for informational and educational purposes only. The views shared are my own and do not represent any organization I am affiliated with. This is not legal, financial, or reimbursement advice, and you should consult your internal experts before making decisions.

Medicare reimbursement changes throughout the year through annual rulemaking, quarterly updates, ASP files, HCPCS changes, and new effective dates. In this episode of Revenue RX, we walk through the CMS reimbursement calendar month by month so pharmacy, finance, and revenue cycle teams know when to audit claims, model proposed changes, prepare for final rules, and validate builds before payment issues appear. Takeaways January, April, July, and October are key quarterly reimbursement checkpoints.April typically begins IPPS proposed rule season.July is a major month for OPPS and Physician Fee Schedule proposals.October 1 brings new IPPS policies and another quarterly update.November is typically outpatient final rule season. Chapters 00:00 CMS Reimbursement Calendar 00:48 January 01:48 February 02:08 March 02:31 April 03:27 May 03:43 June 04:01 July 05:07 August 05:52 September 06:29 October 06:57 November 07:31 December 08:30 Year at a Glance 09:32 Disclaimer Disclaimer This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

Submitting an appeal is easy. Submitting an appeal that actually addresses why a claim was denied is a different skill. In this episode of Revenue RX, we break down the pharmacy appeals process from both a reimbursement and financial perspective. We start with one of the most important decisions: determining whether a denial requires a corrected claim, reconsideration, or formal appeal. We discuss why the denial code should drive the strategy, how to match documentation to the payer’s specific reason for denial, and what belongs in a strong appeal packet. We also walk through a medical necessity appeal example, including how payer coverage policies, clinical documentation, diagnosis information, and supporting evidence can turn a generic appeal into a defensible case. The goal isn’t to build the thickest appeal packet. It’s to identify the root cause, choose the right pathway, submit evidence that answers the payer’s question, and do it before the deadline. Takeaways Determine whether the denial needs a corrected claim, reconsideration, or formal appeal before escalating.Start with the claim adjustment reason code and investigate the workflow failure behind it.Match supporting documentation directly to the payer’s stated denial reason.Medical necessity appeals should demonstrate how the patient met coverage criteria or why an exception was clinically justified.Include complete claim and patient identifiers to prevent avoidable delays or returns.Track appeal deadlines at the individual claim level with a clear owner and next action.Explore manufacturer replacement programs when appropriate for qualifying high-cost medications.Measure appeal performance using overturn rate, dollars recovered, and the percentage of eligible denials appealed.Strong appeals are focused, evidence-based, timely, and built around the payer’s actual question. Chapters 00:02 Understanding Appeals in Pharmacy and Finance 00:54 Corrected Claim, Reconsideration, or Appeal? 02:17 Start With the Denial Code 04:27 Match the Evidence to the Denial 05:19 Building a Strong Appeal Packet 06:15 Building a Strong Medical Necessity Appeal 08:21 Appeal Deadlines Matter 09:27 Manufacturer Replacement Programs 10:13 Measuring Appeal Performance 11:04 What Makes an Appeal Get Paid 11:54 Disclaimer Disclaimer This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

Fixing a denied claim is not the same as fixing the problem that caused it. In this episode of Revenue RX, we explore how pharmacy revenue cycle teams can move beyond individual claim resolution and build a closed-loop process that prevents recurring denials, underpayments, and reimbursement gaps. We break down how to identify root causes, route issues to the right operational owners, correct upstream workflows and system builds, and turn payer-specific discoveries into institutional knowledge. We also discuss why corrective actions need clear ownership, deadlines, and measurable outcomes—and why successful revenue cycle programs should track not only recovered revenue, but also the revenue losses prevented when claims are paid correctly the first time. Takeaways Resolving a claim recovers revenue; correcting the underlying workflow protects future revenue.Categorizing root causes helps identify the team responsible for fixing the problem.Recurring authorization, documentation, coding, NDC, unit, modifier, and system-build issues should be addressed upstream.Successful appeals can reveal opportunities for prevention when the same denial repeatedly occurs.Education is most effective when teams understand exactly what needs to change and why it affects reimbursement.Every corrective action should have an owner, deadline, and defined method for measuring results.Measurement should focus on the specific denial, underpayment, documentation issue, or workflow that was changed.Prevented revenue loss may never appear on a recovery report, but it can represent some of the most valuable work performed by a mature revenue cycle program.A closed-loop revenue cycle becomes a learning system in which every denial, underpayment, and successful appeal improves future claims. Chapters 00:00 Closing the Loop in Pharmacy Revenue Cycle 01:21 Find the Root Cause 03:40 Fix the Upstream Workflow 04:05 Correct the System Build 05:51 Educate the Right Teams 07:26 Assign Owners and Deadlines 08:26 Measure the Fix 09:21 Recovered vs. Prevented Revenue 10:28 Build a Learning System 11:23 Disclaimer Disclaimer This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

Denial rate alone does not tell the full story of revenue cycle performance. Before a claim can be fixed, teams need to correctly diagnose what actually happened: Was it rejected before adjudication, denied after adjudication, underpaid, paid at zero, or only partially paid? In this episode of Revenue RX, we break down the operational differences between rejections and denials and explain how Claim Adjustment Reason Codes (CARCs), Remittance Advice Remark Codes (RARCs), and group codes work together to provide a clearer picture of claim outcomes. We also explore why clinical and administrative denials require completely different skill sets and workflows, using examples such as CARC 50 for medical necessity, CARC 197 for authorization requirements, and CARC 16 paired with RARCs that identify specific billing or documentation issues. Takeaways A rejection occurs before adjudication, while a denial occurs after the payer processes the claim and makes a payment determination.Rejected claims may not contain CARCs or RARCs because they never reached adjudication.CARCs explain why a payment was adjusted, while RARCs provide additional context about the adjustment.Group codes such as CO, PR, and OA help identify financial responsibility for adjusted amounts.A CARC does not automatically represent a denial; some adjustments are expected contractual or patient-responsibility outcomes.Clinical denials such as medical necessity or experimental and investigational determinations often require pharmacist, nurse, or prescriber involvement.Administrative denials such as missing prior authorization require workflow and operational fixes rather than clinical appeals.CARC 16 demonstrates why CARCs should be interpreted alongside RARCs to identify the actual root cause.Underpayments can create significant revenue leakage without generating a denial or work queue entry.Zero-pay and partial-pay claims must be evaluated against reason codes and contract terms before determining whether payment is correct.Rejections, administrative denials, clinical denials, and underpayments should not all be routed through the same workflow.Denial rate should be evaluated alongside rejection rates, underpayment variance, and zero-pay findings for a more complete view of revenue cycle performance. Chapters 00:00 Introduction 00:38 Rejections vs. Denials 02:16 Claim Adjustment Reason Codes (CARCs), Remittance Advice Remark Codes (RARCs), & Group Codes 03:36 Clinical Denials vs. Administrative Denials 07:22 Underpayments 08:44 Delegate Appropriately 10:43 Disclaimer Disclaimer This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

In this episode of Revenue RX, the focus is on the key performance indicators that matter most across the pharmacy revenue cycle. From front-end authorization and financial clearance to charge capture, denials, underpayments, write-offs, and financial performance, the discussion breaks down how teams can use KPIs to identify risk and drive action. The episode also explains why not every metric deserves a place on a scorecard. A meaningful KPI should influence a decision, trigger an investigation, or lead to a workflow change. By connecting operational measures with financial outcomes, pharmacy revenue cycle teams can better protect patient access, reimbursement, cash, and margin. Takeaways A KPI should be connected to a priority and lead to action, not simply appear on a dashboard.Front-end KPIs such as pre-service authorization rate, authorization turnaround time, scheduled service clearance, and treatment delays can serve as leading indicators of future denials.Mid-cycle KPIs help identify problems with charge capture, reconciliation, billing units, modifiers, and clean claims.Back-end performance should be evaluated using both denial frequency and financial exposure, including denial dollars, preventable denials, recovery, aging, underpayments, and terminal write-offs.Negative-margin administrations, 340B capture, and cost to collect can provide additional insight into financial performance.Segmenting KPIs by payer, medication, drug class, location, and site of care can reveal problems that aggregated results may hide.Every KPI should have an owner responsible for investigating changes and coordinating corrective action.Operational KPIs show teams what needs to be fixed, while financial KPIs help explain to leadership why fixing it matters. Chapters 01:46 Front-end KPIs 04:01 Mid-cycle KPIs 06:24 Back-end KPIs 10:51 Financial KPIs 15:50 Disclaimer Disclaimer This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

CMS’s proposed CY 2027 340B policy could change more than reimbursement. It could change how acquisition decisions, billing modifiers, and drug margin interact. In this episode of Revenue RX, we break down the proposed return of the JG modifier as a payment-triggering modifier, the continued use of TB for certain exempt 340B drugs and providers, and CMS’s proposed new XX modifier for drugs acquired outside the 340B program. Takeaways CMS is proposing to pay certain 340B-acquired drugs at ASP minus 33.4% beginning in CY 2027.JG would identify applicable 340B-acquired drugs and trigger the proposed payment adjustment.TB would continue to identify certain 340B drugs and providers that are exempt from the proposed payment reduction.CMS is proposing a new placeholder modifier, XX, to affirmatively identify separately payable drugs acquired outside the 340B program.Hospitals should begin evaluating acquisition-status data, JG and TB logic, proposed non-340B workflows, and drug-level margin exposure.The policy remains proposed, and comments are due August 31, 2026. Chapters 01:33 How We Got Here 02:34 JG Modifier 03:21 TB Modifier 04:08 XX Modifier 05:07 340B vs. WAC 10:14 What Hospitals Should Do Now 10:54 Disclaimer References CMS CY 2027 Hospital Outpatient Prospective Payment System proposed rule, CMS-1850-PDocket CMS-2026-2344American Hospital Association v. BecerraCMS Outpatient Drug Acquisition Cost Survey, ODACS Disclaimer This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

This episode breaks down how to build an effective team around a complex healthcare function, from identifying the work that needs to be done to determining the right roles, reporting structure, and timing for new hires. The discussion explores how to map responsibilities, avoid common organizational mistakes, and create a team structure that supports both operational execution and long-term growth. Takeaways Start by mapping the functions and responsibilities the team needs to own before deciding on titles or headcount.Define clear roles so accountability does not become fragmented across departments.Build the team around organizational needs, workload, and strategic priorities rather than a one-size-fits-all structure.Reporting structure matters and should support collaboration, visibility, and appropriate decision-making authority.Avoid adding roles without first clarifying ownership, workflows, and expectations.Use workload, complexity, organizational growth, and capability gaps to help determine when additional hiring is justified. Chapters 00:32 Why This Team Matters 01:58 Map the Functions 03:21 Core Team Roles 06:09 How to Build the Team 07:26 Where Should It Report? 08:54 Common Mistakes 10:29 When to Hire 12:51 Disclaimer Disclaimer This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

Pass-through status is not a one-time CMS classification. It is a constantly moving pipeline, with new drugs entering protected payment status while others transition into standard OPPS reimbursement. In this episode of Revenue RX, we use the July 1, 2026 OPPS updates as a real-world case study to break down what changed and what pharmacy revenue cycle teams should be watching. We cover newly coded drugs, biologics, and radiopharmaceuticals entering status indicator G, biosimilars receiving their own pass-through status, products exiting pass-through and moving to status indicator K, and retroactive status indicator changes that may require us to revisit previously submitted claims. Most importantly, we focus on the operational side of pass-through management: building new products into the charge description master promptly, monitoring high-volume drugs as they exit pass-through, reviewing quarterly CMS updates, and creating workflows to identify retroactive reimbursement opportunities. Takeaways • Pass-through status indicator G generally provides a two- to three-year protected payment window under OPPS while CMS collects hospital cost and utilization data. • Biosimilars may qualify for their own pass-through periods even when the underlying molecule is already established in the market. • Drugs exiting pass-through with meaningful organizational utilization should be placed on our margin monitoring list. • Retroactive status indicator changes may create opportunities for us to reassess previously billed claims and determine whether additional reimbursement is appropriate. • We should review CMS status indicators quarterly through Addendum B rather than only during annual updates. • Pharmacy revenue cycle teams should maintain a separate workflow for retroactive status changes and establish reminders to reassess products approaching the end of their pass-through window. Chapters 00:00 The Pass-Through Pipeline 01:02 Quick Recap: Status Indicator G 01:39 July 2026: New Pass-Through Drugs 02:46 Biosimilars Entering Pass-Through 03:39 Drugs Exiting Pass-Through Status 04:35 Retroactive Status Indicator Changes 05:24 Building a Quarterly Monitoring Process 06:50 Disclaimer References CMS Hospital Outpatient Prospective Payment System (OPPS) quarterly updates and Addendum B, July 2026 Disclaimer This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

Every HCPCS code billed under the Outpatient Prospective Payment System (OPPS) is assigned a status indicator. But what do those letter designations mean for reimbursement? In this episode of Revenue RX, we explore how CMS uses OPPS status indicators to determine payment methodology for outpatient services, drugs, biologics, and vaccines. Learn the difference between separately payable, packaged, and non-covered services, why status indicators matter for pharmacy reimbursement, and how understanding these payment rules can help prevent costly billing mistakes. The episode explores key pharmacy-related status indicators, including G, H, K, L, N, and E. It also explains the purpose of pass-through payment, what happens when pass-through status expires, and why losing pass-through does not necessarily mean losing reimbursement. Lubna shares practical memory aids and highlights common operational mistakes involving packaged services, Charge Description Master (CDM) maintenance, and reporting requirements. Whether you are new to OPPS or looking for a refresher on CMS payment methodology, this episode provides a practical framework for interpreting status indicators with confidence. Takeaways Understand what OPPS status indicators are and how CMS uses them to determine payment methodology.Learn the difference between separately payable, packaged, and non-covered services.Review the pharmacy-related status indicators G, H, K, L, N, and E.Understand the purpose of pass-through payment and why it is temporary.Learn what happens when a drug transitions from pass-through to non-pass-through status.Recognize that non-pass-through does not automatically mean packaged.Avoid common reimbursement mistakes related to status indicator interpretation.Understand why packaged services with Status Indicator N should still be reported on claims.Learn why maintaining an up-to-date Charge Description Master (CDM) is essential for accurate reimbursement expectations.Use simple memory tricks to remember commonly used OPPS status indicators. Chapters 00:00 Introduction 00:19 What Is a Status Indicator? 01:42 Important Pharmacy Status Indicators 02:57 Pass-Through vs. Non-Pass-Through Payment 04:39 Memory Tricks for Status Indicators 05:30 Common Billing Mistakes to Avoid 06:37 Disclaimer References Medicare Claims Processing Manual, Chapter 4, Hospital Outpatient Prospective Payment SystemNoridian Healthcare Solutions. OPPS Payment Status Indicators. Available at: Noridian OPPS Payment Status Indicators Disclaimer This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.

In this episode of Revenue RX, we discuss why the NDC/HCPCS crosswalk serves as the "Rosetta Stone" of pharmacy billing, translating the language of pharmacy (NDCs) into the language of medical billing (HCPCS codes). TakeawaysUnderstand the purpose of the NDC/HCPCS Crosswalk and why it is essential for pharmacy billing.Learn why NDC-to-HCPCS relationships are at times many-to-one or one-to-many rather than simple one-to-one mappings.Explore real-world crosswalk examples involving prednisone, enoxaparin, normal saline, argatroban, and buprenorphine.See how HCPCS billing units are calculated using drugs such as pembrolizumab and rituximab.Discover why quarterly CMS crosswalk updates are critical for maintaining an accurate CDM and compliant billing workflows.Understand how payer-specific crosswalks can differ from CMS guidance and contribute to claim edits and denials. Chapters 00:00 Introduction 00:27 The Rosetta Stone of Pharmacy Billing 01:52 Real-World Crosswalk Examples 04:08 Billing Units and Quarterly Updates 06:00 Payer Differences Disclaimer This podcast is intended for informational and educational purposes only. The views expressed are personal opinions and do not represent those of any employer or affiliated organization. This content does not constitute legal, financial, compliance, reimbursement, or clinical advice. Healthcare regulations, payer policies, and reimbursement requirements vary by organization and jurisdiction. Always consult your internal compliance, legal, finance, revenue cycle, and operational teams before implementing any strategy discussed in this episode.